Professional Summary
Professional Overview
Mike Kagey is an accomplished leader in the field of translational medicine, currently serving as the Vice President of Translational Medicine at Leap Therapeutics. With extensive expertise in research and development, Kagey has been instrumental in driving advancements in the biopharmaceutical industry.
Experience Summary
Current Role
As the Vice President of Translational Medicine at Leap Therapeutics, Kagey is responsible for overseeing the company's translational research efforts. He leads a team of scientists and researchers in the development of novel therapeutic approaches, focusing on the translation of basic scientific discoveries into potential clinical applications. Kagey's strategic leadership and depth of knowledge have been crucial in guiding Leap Therapeutics' portfolio of innovative drug candidates.
Career Progression
Prior to his current role, Kagey held progressive positions at Leap Therapeutics, serving as the Senior Director of Translational Medicine and the Director of Translational Research. In these roles, he played a pivotal role in the advancement of the company's pipeline, contributing to the successful development of several investigational therapies. Before joining Leap Therapeutics, Kagey gained valuable experience as a Research and Development scientist at Tensha Therapeutics, which was later acquired by Roche.
Kagey's academic background includes a Ph.D. from the University of Virginia, where he specialized in relevant fields. He also completed a postdoctoral fellowship at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology (MIT), further honing his expertise in translational research.
Areas of Expertise
Kagey's areas of expertise include:
- Translational medicine and drug development
- Preclinical research and development
- Oncology and immuno-oncology
- Scientific strategy and program management
- Cross-functional collaboration and team leadership
Professional Impact
Throughout his career, Kagey has made significant contributions to the advancement of translational medicine. His work has led to the development of several promising drug candidates, which have the potential to address unmet medical needs in various therapeutic areas. Kagey's innovative approaches and collaborative leadership have earned him recognition within the industry, positioning him as a respected authority in the field of translational research.
Conclusion
With his extensive experience, strong scientific background, and proven track record of success, Mike Kagey is a valuable asset to Leap Therapeutics. As the Vice President of Translational Medicine, he continues to drive the company's research and development efforts, contributing to the advancement of novel therapies that have the potential to transform patient care.
